Drug Patent Watch
JUNE 7, 2022
This article was originally published by Guy Shtar, Louise Azulay, Omer Nizri, Lior Rokach & Bracha Shapira in Scientific Data volume 9, Article number: 263 under a Creative Commons Attribution…. The post CDCDB: A large and continuously updated drug combination database appeared first on DrugPatentWatch - Make Better Decisions.
Drug Discovery Today
JUNE 2, 2022
The topic of this month’s newsletter from Drug Discovery Today is “Cancer”.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Channels
JUNE 21, 2022
National Association of Specialty Pharmacy (NASP) 2022 Annual Meeting & Expo. September 19-22, 2022 | Gaylord Palms Resort & Convention Center | Orlando, FL. www.naspnet.org/annualmeeting. The National Association of Specialty Pharmacy (NASP) will host the NASP 2022 Annual Meeting & Expo September 19-22. NASP will celebrate their 10th Anniversary and welcome attendees to a new conference venue – the gorgeous Gaylord Palms Resort & Convention Center, located in Orlando, Florida.
Olympian Clinical Research
JUNE 10, 2022
Atopic dermatitis is a form of eczema and is the most common chronic inflammatory skin disease. While this condition is often seen in children, around 16.5 million Americans suffer from this itchy skin condition. Although there is no cure for this condition, with the proper knowledge, treatments, and lifestyle changes, those with eczema may manage their symptoms and lead happy, healthy lives.
Speaker: Simran Kaur, Co-founder & CEO at Tattva.Health
AI is transforming clinical trials—accelerating drug discovery, optimizing patient recruitment, and improving data analysis. But its impact goes far beyond research. As AI-driven innovation reshapes the clinical trial process, it’s also influencing broader healthcare trends, from personalized medicine to patient outcomes. Join this new webinar featuring Simran Kaur for an insightful discussion on what all of this means for the future of healthcare!
Pharma Manufacturing
JUNE 28, 2022
Advanced digital thread and technology transfer capabilities can help pharma reap the benefits of its processes
Drug Discovery Digest brings together the best content for drug research and development professionals from the widest variety of industry thought leaders.
Drug Patent Watch
JUNE 29, 2022
Annual Drug Patent Expirations for AUSTEDO Austedo is a drug marketed by Teva Branded Pharm and is included in one NDA. It is available from one supplier. There are seven…. The post New patent for Teva Branded drug AUSTEDO appeared first on DrugPatentWatch - Make Better Decisions.
Advarra
JUNE 30, 2022
The post Expanding the Ecosystem to Better Serve You appeared first on Advarra.
Drug Channels
JUNE 6, 2022
Time for an update to the Drug Channels Institute (DCI) annual analysis of pharmacist salaries and employment. The retail pharmacy shakeout affected 2021 pharmacist employment. We found that retail pharmacies and drugstores employed fewer pharmacists, while hospitals and outpatient centers continued to add positions. As a result, the share of pharmacists who work in non-retail practice settings reached a new high.
ProRelix Research
JUNE 29, 2022
According to the World Health Organization (WHO), cancer is the leading cause of death worldwide, accounting for nearly 10 million deaths in 2020 (1). In addition, GLOBACAN estimated 19.3 […]. The post Oncology Bioequivalence Clinical Studies appeared first on ProRelix Research.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Pharma Manufacturing
JUNE 24, 2022
Pharma can do better than 50% compliance
Crown Bioscience
JUNE 28, 2022
Precision medicine and immunotherapy continue to top the list as two of the hottest areas in cancer research. In this blog post we explore how immuno-oncology can draw from precision medicine to create more personalized cancer therapies to enhance their safety and efficacy. Read on to review how ICIs, neoantigen vaccines and adoptive cell therapies, including CAR-T, CAR-NK, CAR-M, TCR-T and TIL therapies, are advancing this remarkable field of science and medicine.
Drug Patent Watch
JUNE 29, 2022
Annual Drug Patent Expirations for ORILISSA Orilissa is a drug marketed by Abbvie Inc and is included in one NDA. It is available from one supplier. There are five patents…. The post New patent for Abbvie Inc drug ORILISSA appeared first on DrugPatentWatch - Make Better Decisions.
Altus Drug Development
JUNE 28, 2022
Ensuring access to safe and effective treatments is the main challenge faced by pharmaceutical companies big and small. Value-added medicines offer an efficient method to meet the needs of patients while stimulating innovation in the pharmaceutical industry. What is a value-added medicine? Value-added medicines are novel drug products created to provide improvements for patients that can’t be achieved using traditional therapeutic methods.
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Drug Channels
JUNE 2, 2022
Today’s guest post comes from Bonnie Briggs, Associate Director of Clinical Effectiveness at Wolters Kluwer, Health. Bonnie describes how pharmaceutical care would benefit from standard medical record identification. She then discusses the practical issues behind implementing and adopting such a system. To learn more, download the Wolters Kluwer free ebook: Drug Data Unity: Realistic and Idealistic Futures for Information Exchange.
Advarra
JUNE 28, 2022
As a drug successfully makes it through the development process, sponsors will inevitably need to submit a new drug application (NDA) to the Food and Drug Administration (FDA). While it may seem like a straightforward process to some, there’s room for many elements to be missed as sponsors prepare for the application submission. Failure to Have a Pre-Investigational New Drug (IND) Meeting.
Olympian Clinical Research
JUNE 28, 2022
Prurigo nodularis is a skin condition characterized by the development of small nodular lesions, which are often severely itchy. People afflicted with this disease may develop a few lesions or potentially over 200, all of which with varying sizes. Often confused with other skin conditions, prurigo nodularis symptoms may resemble eczema or psoriasis, making it challenging to diagnose and treat. .
Crown Bioscience
JUNE 27, 2022
This article originally appeared on Labiotech.eu in July 2022 and is written by Alexander Burik. Large-panel cancer cell line screening can help find the right fit between a specific cancer cell and a therapeutic molecule, leading to the development of effective treatments. How can robust quality control, real-time screening methods, and a set of unique screening panels address current screening challenges?
Advertisement
Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.
Drug Patent Watch
JUNE 30, 2022
Annual Drug Patent Expirations for LUSEDRA Lusedra is a drug marketed by Eisai Inc and is included in one NDA. There is one patent protecting this drug. This drug has…. The post New patent expiration for Eisai Inc drug LUSEDRA appeared first on DrugPatentWatch - Make Better Decisions.
sptlabtech
JUNE 27, 2022
"For the last couple of years, we've been Covid testing and have been very successful with the SPT Labtech liquid handlers." Farruk Kabir | NGS Lab Manager | Aperture NextGen Laboratories Aperture NextGen Laboratories is an FDA approved CLIA lab for interdisciplinary clinical testing and research. Over the course of the pandemic, the team of around 15 to 20 lab staff based in Plano, Texas, has been busy testing for SARS-CoV-2 and developing proprietary NGS protocols.
Drug Channels
JUNE 29, 2022
I can’t recall any period in my life when our country has been so divided and polarized. Through the Drug Channels Institute, I strive to provide you with fact-based and balanced coverage—along with links to source materials so you can make up your own mind. So before you launch your July 4 festivities and/or a civil war, Drug Channels humbly offers some data fireworks for our troubled nation: More evidence of slow growth in drug spending for 2021 Fresh data on skyrocketing PBM formulary exclusi
Atomwise Blog
JUNE 27, 2022
Our scientists have developed a set of chemical benchmarks to better understand exactly what our computational models are learning. At Atomwise, AtomNet® structure-based models can quickly identify active compounds for protein targets from large chemical libraries for drug discovery projects. Understanding how models recognize features of molecular activity can shed light on, for example, important receptor-ligand interactions, biases toward particular functional groups, or target selectivity of
Advertisement
Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic
The Open Targets Blog
JUNE 24, 2022
The latest release of the Platform — 22.06 — is now available at platform.opentargets.org. Key points We have included five additional studies in our Gene Burden widget, incorporating evidence from a number of different therapeutic areas The term “ medical procedure ” has been added to our ontology Users can now visualise subcellular locations of targets Key stats Metric Count Targets 61,524 Diseases 23,074 Drugs 12,854 Evidence strings 14,455,104 Associations 7,247,8
Crown Bioscience
JUNE 22, 2022
Do you ever wonder how tumor organoids and ex vivo microtumors (i.e., patient tumor material) are being used in immuno-oncology (I/O)?
Drug Patent Watch
JUNE 27, 2022
Annual Drug Patent Expirations for XYREM Xyrem is a drug marketed by Jazz Pharms and is included in one NDA. It is available from one supplier. There are eight patents…. The post New patent for Jazz Pharms drug XYREM appeared first on DrugPatentWatch - Make Better Decisions.
EG Life Sciences
JUNE 22, 2022
The pharmaceutical industry is one of the most highly regulated industries, and for good reason. These organizations are tasked with protecting the rights and well-being of subjects, along with the integrity of data and analysis. As a result, audits are a crucial part of our business.
Drug Channels
JUNE 14, 2022
Last week, the authors of a new JAMA study claimed that “prices for new drugs are skyrocketing.” Their research, along with a simultaneously released New York Times op-ed, received widespread media coverage. Links below. But as I explain, the study’s headline conclusion is highly misleading. The authors obscure the real story with mathematical sleight-of-hand that misrepresents the underlying data and overlooks the true nature of today’s pharmaceutical innovations.
Expert insights. Personalized for you.
119 
Let's personalize your content